Autoimmune diseases like psoriasis affect millions around the world. These conditions cause the immune system to attack healthy tissues, leading to painful inflammation, scaly skin patches, and joint issues in some cases. Traditional treatments often fall short, leaving patients searching for better options.
Nanobodies represent a fresh approach in this field. Derived from camelid antibodies, these are tiny protein fragments, much smaller than standard antibodies used in most drugs. That small size lets them reach hidden spots in inflamed tissues where bigger molecules struggle.
Researchers prize nanobodies for their stability and precision. They can target specific proteins driving inflammation, like interleukins, with fewer side effects. In autoimmune therapies, companies use them to block culprits such as IL-17, a key player in psoriasis plaques and related conditions.
Psoriasis impacts over 125 million people globally, with no cure yet. Current biologics inhibit single inflammatory signals, but many patients see only partial relief, around 50-70% skin improvement at best. The market for these drugs exceeds $30 billion yearly, yet gaps remain for those needing complete clearance.
Sonelokimab stands out here. Developed by MoonLake Immunotherapeutics (NASDAQ: MLTX), it blocks both IL-17A and IL-17F isoforms at once. Phase 2 trials showed up to 77% of patients achieving near-perfect skin clearance (PASI 90), far above placebo rates of 15%.
This dual action could offer superior results over rivals like secukinumab or ixekizumab. MoonLake focuses on hard-to-treat areas, including hidradenitis suppurativa alongside psoriasis, building a pipeline for inflammatory skin disorders.
Over the weened MoonLake shared positive news from its final pre-BLA meeting with the U.S. FDA. Regulators agreed on the data package for sonelokimab’s Biologics License Application in psoriasis, including adult and adolescent trial results from studies like MIRA.
This green light confirms the path forward. MoonLake now plans BLA submission by late September 2026, with FDA acceptance likely within 60 days. It reduces uncertainty, aligning endpoints on efficacy and safety that trials already met.
The meeting covered adolescent data inclusion, broadening potential approval. For a small-cap biotech like MoonLake, with no products on market yet, this step validates years of development.
MoonLake also reported Q1 2026 results that day. Cash reserves stood strong at levels supporting operations through key milestones, with R&D expenses reflecting ongoing trials. No revenue yet, as expected for a clinical-stage firm, but burn rate remains controlled.
Market reaction followed swiftly. MLTX shares rose over 10% at market open today, trading close to $19. Analysts like H.C. Wainwright raised price targets, citing the de-risked approval timeline.
This FDA alignment positions sonelokimab for potential 2027 launch if approved. Success could tap a psoriasis segment worth billions, especially for non-responders to existing IL-17 drugs. MoonLake’s nanobody platform extends to other autoimmune areas, like axial spondyloarthritis, with positive phase 2 data already in hand. These milestones show how regulatory nods can shift company trajectories overnight. The nanobody field grows, promising more targeted relief for chronic sufferers.
